Company intelligence / Profile preview

ALPCO

Salem, New Hampshire, United Statesalpco.com ↗

Ownership: Private
Employees: ~73
Development stage: Commercial

Overview

ALPCO provides commercialized diagnostic products globally. Their portfolio includes FDA registered in vitro diagnostic assays such as the Calprotectin Immunoturbidimetric Assay for intestinal inflammation; multiplex PCR kits for STI detection; chemiluminescent ELISAs; allergy explorer panels; and a range of specialty immunodiagnostic reagents. The merger with GeneProof expanded their reach into advanced molecular diagnostics.

Therapeutic areas: OncologyEndocrinologyImmunologyHematologyGastroenterologyInfectious Diseases
Modalities: Immunoassay-based diagnostics (Immunodiagnostics)Molecular diagnostics (including PCR-based assays)ELISA kits and platformsChemiluminescence immunoassays
Industry: Molecular Diagnostics

Partnerships

Ampersand Capital Partners invested in ALPCO in May of 2020.

Beyond the preview

Go deeper on ALPCO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALPCO.

Explore the full profile